Leniolisib
Phase 3Active 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedAbout Leniolisib
Leniolisib is a phase 3 stage product being developed by Pharming Group for APDS. The current trial status is active. This product is registered under clinical trial identifier NCT05693129. Target conditions include APDS.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06990529 | Phase 2 | Recruiting |
| NCT05693129 | Phase 3 | Active |
| NCT05438407 | Phase 3 | Active |
Competing Products
2 competing products in APDS
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Leniolisib | Pharming Group | Phase 3 | 72 |
| CDZ173 | Novartis | Phase 2/3 | 65 |